文献速递免疫规划

高剂量细胞基质佐剂四价流感疫苗的免疫原性与安全性

Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies.
PubMed 文献 · Vaccine · 2026-03-19

两项随机对照2期研究在≥50岁人群中评估了不同抗原和MF59佐剂剂量的细胞基质佐剂四价流感疫苗(aQIVc)的免疫原性与安全性。结果显示,aQIVc[45,2×]免疫应答最高,所有毒株GMT比值优于QIVc[15,0×],且未发现安全性问题。

要点

  • aQIVc免疫应答随抗原和佐剂剂量增加而增强,2×与3×佐剂间相似。
  • aQIVc[45,2×]对全部毒株的GMT比值优于QIVc[15,0×]。
  • aQIVc[45,2×]局部和全身不良事件率最高(71.1%),但多为轻中度。

核心结论

  • aQIVc[45,2×]在≥50岁人群中免疫应答最高,且未发现安全性问题。
  • 该配方被选入后续3期研究(NCT06015282)。

研究设计与样本

  • 两项2期、观察者盲法、多中心、随机对照研究(V201_01剂量探索和V201_07剂量确认),对象为≥50岁人群。
  • V201_01暴露838人,随机接受7种aQIVc配方或非佐剂QIVc(15μg HA/株);V201_07暴露1051人,随机接受aQIVc[45,1×]、aQIVc[45,2×]、QIVc[45,0×]或QIVc[15,0×]。
  • 主要目标为接种后28天评估aQIVc相比QIVc的免疫原性。

主要发现

  • V201_01中,aQIVc对比QIVc的GMT比值随抗原和佐剂剂量增加而升高,但2×与3×佐剂间相似。
  • V201_07中,aQIVc[45,2×]对比QIVc[15,0×]的GMT比值范围为1.27(95%CI 1.04,1.55)至1.86(1.52,2.27),所有毒株均优效。
  • aQIVc[45,2×]对比QIVc[45,0×]对A/H1N1、A/H3N2和B/Yamagata优效,对B/Victoria非劣效。
  • V201_07中,征集性不良事件(接种后第1-7天)发生率aQIVc[45,2×]最高(71.1%),QIVc[15,0×]最低(50.4%),多为轻中度。

关键数值与推荐

  • 优效性判定标准为GMT比值95%CI下限>1.0。
  • aQIVc[45,2×]对QIVc[15,0×]所有毒株GMT比值1.27(1.04,1.55)至1.86(1.52,2.27)。
  • aQIVc[45,2×]对QIVc[45,0×]的GMT比值在A/H1N1、A/H3N2、B/Yamagata优效,B/Victoria非劣效。

临床怎么用

  • 在≥50岁人群中,aQIVc[45,2×]可能提供比标准剂量非佐剂QIVc更强的免疫应答。
  • 该配方安全性可接受,不良事件多为轻中度。
  • 最终应用需等待3期研究(NCT06015282)验证。

局限性

  • 研究为2期、观察者盲法,样本量有限。
  • 研究对象以白人为主(V201_01 55.9%,V201_07 83.7%),外推需谨慎。
  • 未报告临床保护效力终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal formulation of an adjuvanted cell-based quadrivalent influenza vaccine (aQIVc) was investigated in Phase 2, observer-blind, multicentre, dose-finding (V201_01, NCT04782323) and dose-confirmation (V201_07, NCT05501561) studies in participants aged ≥50 years. In V201_01, participants were randomised to one of seven investigational aQIVc formulations or non-adjuvanted QIVc (15 μg haemagglutinin antigen [HA] per strain). Investigational formulations contained 15, 30, or 45 μg HA per strain, and 1×, 2×, and 3× the dose of MF59 adjuvant included in Fluad®. In V201_07, participants were randomised to aQIVc [45,1×], aQIVc [45,2×], QIVc [45,0×: 45 μg HA, 0×MF59] or QIVc [15,0×: 15 μg HA, 0× MF59]. Primary objective: to assess the immunogenicity of aQIVc formulations vs. QIVc 28 days post-vaccination. In V201_01, 838 participants (47.3% aged ≥65 years; 56.6% female; 55.9% White) were exposed. Generally, covariate-adjusted geometric mean titre ratios (GMTr) of aQIVc vs. QIVc at Day 29 (per-protocol set [PPS; n = 810]) increased with antigen and adjuvant dose but were similar between 2× and 3× adjuvant. In V201_07, 1051 participants (47.9% aged ≥65 years; 58.0% female; 83.7% White) were exposed (PPS; n = 1022). GMTr for aQIVc [45,2×] vs. QIVc [15,0×] ranged from 1.27 (95% confidence interval [CI], 1.04, 1.55) to 1.86 (1.52, 2.27) and were superior (lower limit of 95% CI >1.0) for all strains. GMTr of aQIVc [45,2×] vs. QIVc [45,0×] were superior for A/H1N1, A/H3N2, and B/Yamagata, and non-inferior for B/Victoria. Neither study presented safety concerns. In V201_07, rates of solicited adverse events (Day 1-7 post-vaccination) were highest with aQIVc [45,2×] (71.1%) and lowest with QIVc [15,0×] (50.4%); most events were mild (Grade 1) or moderate (Grade 2) severity across all groups. aQIVc [45,2×] demonstrated the highest immune response of all formulations tested, with no safety concerns, and was selected for further investigation in a Phase 3 study (NCT06015282). Clinical trial registry: NCT04782323 (https://clinicaltrials.gov/study/NCT04782323; registered date 2021-03-01), NCT05501561 (https://clinicaltrials.gov/study/NCT05501561; registered date 2022-08-11).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. de Looze F, Essink BJ, van Boxmeer J, et al. Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies. Vaccine. 2026. PMID: 41855648. doi:10.1016/j.vaccine.2026.128436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。